Keywords: Merck & Co, Gardasil, Cervical cancer vaccine, HPV genotyping, SANA Vax

S.A.N.E. Vax calls for temporary withdrawal of Merck & Co’s Gardasil claiming inappropriate endpoint and unreliable HPV genotyping methods used

Article | 27 October 2010

Print This

In a letter addressed to US Food and Drug Administration Commissioner Margaret Hamburg, Norma Erickson, president of the not-for-profit S. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in